A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis

Journal of Investigational Allergology and Clinical Immunology

Volumn 14, Issue 1, 2004, Pages 56-63

  Hampel Jr , Frank ^a   Howland III, W ^b   Van Bavel, J ^c   Ratner, P ^d  

^a Central Texas Health Research   (United States)

^b HealthQuest Research   (United States)

^c Allergy and Asthma Associates   (United States)

^d Sylvana Research   (United States)

Author keywords

Antihistamines; Clinical trial; Ebastine; Loratadine; Seasonal allergic rhinitis

Indexed keywords

EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NOSE CONGESTION; PHARYNGITIS; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SNEEZING; SOMNOLENCE; XEROSTOMIA;

ADMINISTRATION, ORAL; BUTYROPHENONES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LORATADINE; MALE; MULTIVARIATE ANALYSIS; PATCH TESTS; PIPERIDINES; PROBABILITY; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1942505881     PISSN: 10189068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Davies, R.J. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin Drug Invest 1998, 16:413-420.
2. Bousquet, J., Gaudano, E.M., Palma Carlos, A.G., Staudinger, H. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy 1999, 54(6):562-568.
3. De Molina, M., Cadahia, A., Cano, L., Sanz, A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest 1989, 1:40-46.
4. Storms, W.W. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996, 52(Suppl 1):20-25.
5. Gehanno, P., Bremard-Oury, C., Zeisser, P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996, 76(6):507-512.
6. Luria, X., Robert, M., Antepara, I., Basomba, A., Castillo, J.A., Cisteró, A.M., Diaz, M., Fernandez, J., Nevot, S., Picado, C., Pinto, E., Raga, E. A double-blind placebo controlled study of the efficacy and tolerability of ebastine and loratadine in seasonal allergic rhinitis patients. Allergy 1995, 50(26 Suppl.):199 (Abst P-0350).
7. Ratner, P.H., Lim, J.C., Georges, G.C. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. J Allerg Clin Immunol 2000, 105(6):1101-1107.
8. Haria, M., Fitton, A., Peters, D.H. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994, 48(4):617-637.
9. Claritin brand of loratadine tablets. In Physician's Desk Reference. Montvale (NJ): Medical Economics 1999, pp. 2825-2827.
10. Reinberg, A., Gervais, P., Levi, F., Smolensky, M., Del Cerro, L., Ugolini, C. Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods. J Allergy Clin Immunol 1988, 81(1):51-62.
11. Smolensky, M.H., Reinberg, A., Labrecque, G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications. J Allergy Clin Immunol 1995, 95(5 Pt 2):1084-1096.
12. Roberts, D.J., Gispert, J. The non-cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 1999, 29 Suppl 3:151-155.
13. Wiseman, L.R., Faulds, D. Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996, 51(2):260-277.
14. Vincent, J., Sumner, D.J., Reid, J.L. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmacol 1988, 26(5):503-508.
15. Hurst, M., Spencer, C.M. Ebastine - An update of its use in allergic disorders. Drugs 2000, 59(4):981-1006.
16. Connell, L., Alderfer, V., García, J. Electrocardiographic evaluation of ebastine in double-blind allergic rhinitis clinical trials. Allergy 1995, 50(Suppl 26):105.